NetworkNewsBreaks

MondayFeb 26, 2018 3:12 pm

NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Enters Agreement to Create Unique Analytical System Using Patented Pressure Cycling Technology

Pressure BioSciences (OTCQB: PBIO) recently entered a global co-marketing and distribution agreement with ISS, Inc. to create an advanced high pressure optical spectroscopy system utilizing PBIO’s patented pressure cycling technology (“PCT”). An article further discussing the agreement reads: “A leading developer and provider of innovative high pressure-based solutions to the global life sciences industry, Pressure BioSciences, Inc. (OTCQB: PBIO) has entered a two-year agreement with ISS, Inc., a prominent designer and manufacturer of advanced scientific instruments with more than 30 years of experience in the field. Under the agreement, the two companies will join their marketing and distribution efforts worldwide,…

Continue Reading

MondayFeb 26, 2018 2:49 pm

NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Focuses on Completing Key Projects in 2018

Science-based biotechnology company Earth Science Tech, Inc. (OTC: ETST) has set its sights on a momentous year in 2018 with many noteworthy tasks on the horizon. An article discussing the company reads: “Earth Science Tech, Inc. (OTC: ETST) is working toward an uplisting to the OTCQB Venture Market in early 2018. It has also retained counsel for a planned Regulation A+ Tier 2 round of financing, which the company hopes will raise an aggregate of $4 million (http://nnw.fm/If7xI). The funds would be used to finance its planned projects in the new year and for general working capital (http://nnw.fm/AvqM6), with share…

Continue Reading

MondayFeb 26, 2018 11:24 am

NetworkNewsBreaks – Consorteum Holdings, Inc. (CSRH) Mobile 359 Subsidiary Inks Deal with DevLex to Launch Predictive Analytics Platform

Software development and mobile solutions company Consorteum Holdings (OTC: CSRH) today announced that its wholly owned subsidiary, 359 Mobile Inc., has inked a new partnership deal with DevLex Ltd. The deal seeks to augment DevLex’s predictive analytics platform (“DV-PA”) with 359’s Universal Mobile Interface™ ("UMI"). 359’s flagship product, UMI, was recently integrated to facilitate a multitude of FinTech-based services. The alliance will expand the DV-PA platform to a range of vertical market solutions of 359 to new sectors like FinTech, sports wagering, commodities management, and other record-based, data management sectors. "DevLex's expertise in complex localized large scale predictive analytics is…

Continue Reading

MondayFeb 26, 2018 10:55 am

NetworkNewsBreaks – IEG Holdings Corp. (IEGH) Signs Intellectsoft for Cryptocurrency Blockchain Development Services; Discloses Potential Philippines Cryptocurrency Remittance Strategy

IEG Holdings Corp. (OTCQB: IEGH) this morning announced that Investment Evolution Crypto LLC, its wholly owned subsidiary, has outsourced Intellectsoft LLC to offer blockchain development services including functional and business requirement analysis; technical and market research; and a development plan for the development of IEG Holdings' cryptocurrency. IEGH also revealed that its subsidiary is planning to penetrate the Filipino USD 28 billion Overseas Foreign Workers (“OFWs”) remittance market, by developing and launching a cryptocurrency targeting both the Australian and US based Philippines OFWs. Per the update, its subsidiary is in the initial stages of these plans, and it will investigate…

Continue Reading

MondayFeb 26, 2018 10:14 am

NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Appoints Director of International Operations

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced its appointment of Dr. Maher Khaled to the position of director of international operations. Khaled bolsters the PreveCeutical team with more than a decade of experience in commercializing therapeutic and diagnostic technologies, most recently at UniQuest Pty Ltd. Moving forward, he will be involved in overseeing PreveCeutical’s development of therapeutic technologies, as well as managing the company’s ongoing operations in Australia, reviewing acquisition and licensing opportunities and leading commercialization efforts for its growing IP portfolio. “We are delighted to have Dr. Khaled as part of…

Continue Reading

MondayFeb 26, 2018 9:29 am

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Global Licensing Agreement with Neutrisci International Inc. (TSX-V: NU) (OTCQB: NRXCF)

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning said it has entered an agreement with NeutriSci International Inc. (TSX-V: NU) (OTCQB: NRXCF) resulting in NeutriSci now having 100% ownership of Ambarii Trade Corporation. Lexaria has also granted to NeutriSci an Intellectual Property License and Supply Agreement for the manufacturing and sale of CBD based products. Per the License Agreement, NeutriSci will remain focused on the development and sales of its existing and pipeline products that include Lexaria's technology for enhancing palatability and bioavailability of beneficial non-psychoactive cannabinoids. Lexaria will receive continuing royalty revenues from the sales generated by these products.…

Continue Reading

MondayFeb 26, 2018 9:09 am

NetworkNewsBreaks – PotNetwork Holding, Inc. (POTN) Subsidiary Records More than $270,000 in Sales at CHAMPS Trade Show

PotNetwork Holding, Inc. (OTC: POTN), through wholly-owned subsidiary Diamond CBD, Inc., this morning announced that it recorded over $270,000 in sales at the 37th CHAMPS Trade Show, which took place at the Las Vegas Convention Center from February 19-21, 2018. Diamond CBD continued to build on its highly successful history of sales at such events at the CHAMPS winter show, its first major trade show of 2018. Per the update, the company’s performance at the show surpassed past records of trade show sales for its CBD product line. “Without a mistake, Diamond CBD is off to a great start in…

Continue Reading

FridayFeb 23, 2018 1:42 pm

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Closes $9M Registered Direct Offering

Clinical stage pharmaceutical company Moleculin Biotech (NASDAQ: MBRX) has closed its offering of 4.29 million registered shares of common stock at a purchase price of $2.10 per share. Concurrently in a private placement, for each share of common stock purchased by an investor, the investor will receive an unregistered warrant to purchase 0.5 of a share of common stock. The warrants are exercisable six months from the date of issuance at a price of $2.80 per share and will expire five years from the initial exercise date. Moleculin intends to use the gross proceeds from the offering, which total approximately…

Continue Reading

FridayFeb 23, 2018 11:08 am

NetworkNewsBreaks – SinglePoint, Inc. (SING) CEO Discusses Recent LOI, Acquisition Strategy in Interview on MoneyTV

Specialized holding company SinglePoint, Inc. (OTCQB: SING) was a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program discussing “money and what makes it happen.” In this week’s episode, SinglePoint CEO Greg Lambrecht discussed the company’s recently announced Letter of Intent (“LOI”) with ORHub, Inc. (OTC: ORHB) to develop a blockchain services platform for health care applications. Per the agreement, ORhub will engage SinglePoint for up to $750,000 in initial development costs. Lambrecht also updated viewers on the company’s plans for 2018, including its aggressive acquisition strategy moving forward. Per the…

Continue Reading

FridayFeb 23, 2018 10:29 am

NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Signs Agreement to Acquire Sechelt Organic Marijuana Corp.

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), a pharmaceutical and IP development firm, this morning announced that it has signed an agreement with 906474 ALBERTA LTD (“the vender”), to purchase 100% ownership of Sechelt Organic Marijuana Corp (“SOM”). Under the agreement, Veritas Pharma will purchase all outstanding shares of SOM at a price of $800,000, subject to provisions of the closing agreement. The agreement requires the vender and SOM to give Veritas Pharma unlimited access to the operations, assets, properties, and records of SOM to help it familiarize with the operations, assets, records, properties and other matters on continuous…

Continue Reading